Selective Estrogen Receptor Modulators – turning point in therapy of menopause

Artur J. Jakimiuk; Michał Bogusiewicz

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2002
vol. 1

Send email

Copy url:

abstract:

Selective Estrogen Receptor Modulators – turning point in therapy of menopause

Artur J. Jakimiuk

,

Michał Bogusiewicz

(Prz Menopauz 2002, 4: 14–24)

Online publish date: 2004/03/03

View full text Get citation

Selective Estrogen Receptor Modulators (SERMs) are compounds, which reveal estrogenic or antiestrogenic activity, depending on target tissue. SERMs act through estrogen receptors. Their selectivity is associated with different affinity to estrogen receptors a and b, tissue distribution of both receptors as well as presence of transcription coactivators and corepressors in the cell. Tamoxifen, a SERM of first generation, since over 20 years is used in prevention and treatment of breast cancer. Recently, it has been proposed that reduction of drug dose may decrease the incidence of adverse events without loss of therapeutic efficacy. Raloxifene is the first SERM approved for prevention and treatment of postmenopausal osteoporosis. It prevents from vertebral fractures and increases bone mineral density. Moreover, the drug decreases the risk of breast cancer, beneficially affects lipoprotein metabolism and declines serum concentrations of arteriosclerosis markers.

keywords:

Selective Estrogen Receptor Modulators – turning point in therapy of menopause

Artur J. Jakimiuk , Michał Bogusiewicz

selective estrogen receptor modulators, menopause

Artur J. Jakimiuk

,

Michał Bogusiewicz